Richard W. Dugan
Director/Board Member presso VANDA PHARMACEUTICALS INC.
Patrimonio netto: 401 547 $ in data 31/03/2024
Profilo
Richard W.
Dugan is currently the Lead Independent Director at Vanda Pharmaceuticals, Inc. He previously held positions as Director at Middlebrook Pharmaceuticals, Inc. from 2003 to 2010, Director at Critical Therapeutics, Inc. from 2004 to 2008, and Director at Antisoma, Inc. He also served as Senior Partner at Ernst & Young LLP from 2001 to 2002.
Mr. Dugan obtained his undergraduate degree from The Pennsylvania State University.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 08/06/2023 | 97 700 ( 0.17% ) | 401 547 $ | 31/03/2024 |
Posizioni attive di Richard W. Dugan
| Società | Posizione | Inizio |
|---|---|---|
| VANDA PHARMACEUTICALS INC. | Director/Board Member | 01/12/2005 |
Precedenti posizioni note di Richard W. Dugan
| Società | Posizione | Fine |
|---|---|---|
Middlebrook Pharmaceuticals, Inc.
 Middlebrook Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology MiddleBrook Pharmaceuticals, Inc. develops and commercializes anti-infective drug products. It operates mainly in prescription pharmaceuticals. MiddleBrook's main product is PULSYS. PULSYS technology offers the prolonged release and absorption of a drug. The company was incorporated in December 1999 and is headquartered in Westlake, TX. | Director/Board Member | 03/08/2010 |
| Critical Therapeutics, Inc. | Director/Board Member | 04/11/2008 |
Ernst & Young LLP
 Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | Corporate Officer/Principal | 01/09/2002 |
Antisoma, Inc.
 Antisoma, Inc. Pharmaceuticals: MajorHealth Technology Antisoma, Inc. develops drugs and pharmaceuticals. The firm's products include Xanafide, Symadex, and Clomet. Its products are used in clinical and preclinical development for multiple cancer indications. The company was founded in 2001 and is headquartered Cambridge, MA. | Director/Board Member | - |
Formazione di Richard W. Dugan
| The Pennsylvania State University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| VANDA PHARMACEUTICALS INC. | Health Technology |
| Aziende private | 4 |
|---|---|
Ernst & Young LLP
Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | Commercial Services |
| Critical Therapeutics, Inc. | Health Technology |
Middlebrook Pharmaceuticals, Inc.
Middlebrook Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology MiddleBrook Pharmaceuticals, Inc. develops and commercializes anti-infective drug products. It operates mainly in prescription pharmaceuticals. MiddleBrook's main product is PULSYS. PULSYS technology offers the prolonged release and absorption of a drug. The company was incorporated in December 1999 and is headquartered in Westlake, TX. | Health Technology |
Antisoma, Inc.
Antisoma, Inc. Pharmaceuticals: MajorHealth Technology Antisoma, Inc. develops drugs and pharmaceuticals. The firm's products include Xanafide, Symadex, and Clomet. Its products are used in clinical and preclinical development for multiple cancer indications. The company was founded in 2001 and is headquartered Cambridge, MA. | Health Technology |
- Borsa valori
- Insiders
- Richard W. Dugan
